Table of Contents
International Journal of Molecular Imaging
Volume 2011 (2011), Article ID 548123, 11 pages
http://dx.doi.org/10.1155/2011/548123
Research Article

Comparison of Cannabinoid CB1 Receptor Binding in Adolescent and Adult Rats: A Positron Emission Tomography Study Using [18F]MK-9470

1Schizophrenia Research Institute, Sydney, Australia
2ANSTO LifeSciences, ANSTO, PMB 1 Menai, Sydney, Australia
3School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
4Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW, Australia

Received 16 August 2011; Accepted 17 September 2011

Academic Editor: Guy Bormans

Copyright © 2011 Mathieu Verdurand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Di Marzo, A. Fontana, H. Cadas et al., “Formation and inactivation of endogenous cannabinoid anandanide in central neurons,” Nature, vol. 372, no. 6507, pp. 686–691, 1994. View at Google Scholar · View at Scopus
  2. J. M. McPartland, “Phylogenomic and chemotaxonomic analysis of the endocannabinoid system,” Brain Research Reviews, vol. 45, no. 1, pp. 18–29, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. C. Howlett, F. Barth, T. I. Bonner et al., “International union of pharmacology. XXVII. Classification of cannabinoid receptors,” Pharmacological Reviews, vol. 54, no. 2, pp. 161–202, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. Devane, L. Hanus, A. Breuer et al., “Isolation and structure of a brain constituent that binds to the cannabinoid receptor,” Science, vol. 258, no. 5090, pp. 1946–1949, 1992. View at Google Scholar · View at Scopus
  5. R. Mechoulam, S. Ben-Shabat, L. Hanuš et al., “Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors,” Biochemical Pharmacology, vol. 50, no. 1, pp. 83–90, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Piomelli, “The molecular logic of endocannabinoid signalling,” Nature Reviews Neuroscience, vol. 4, no. 11, pp. 873–884, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. R. I. Wilson and R. A. Nicoll, “Neuroscience: endocannabinoid signaling in the brain,” Science, vol. 296, no. 5568, pp. 678–682, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. C. Azad, M. Eder, G. Marsicano, B. Lutz, W. Zieglgänsberger, and G. Rammes, “Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse,” Learning and Memory, vol. 10, no. 2, pp. 116–128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. G. L. Gessa, M. Melis, A. Muntoni, and M. Diana, “Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors,” European Journal of Pharmacology, vol. 341, no. 1, pp. 39–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Tsou, K. Mackie, M. C. Sañudo-Peña, and J. M. Walker, “Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation,” Neuroscience, vol. 93, no. 3, pp. 969–975, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Herkenham, A. B. Lynn, M. R. Johnson, L. S. Melvin, B. R. De Costa, and K. C. Rice, “Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study,” Journal of Neuroscience, vol. 11, no. 2, pp. 563–583, 1991. View at Google Scholar · View at Scopus
  12. V. Di Marzo and L. D. Petrocellis, “Plant, synthetic, and endogenous cannabinoids in medicine,” Annual Review of Medicine, vol. 57, pp. 553–574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Fernandez-Ruiz and S. Gonzales, “Cannabinoid control of motor function at the basal ganglia,” Handbook of Experimental Pharmacology, no. 168, pp. 479–507, 2005. View at Google Scholar
  14. G. Riedel and S. N. Davies, “Cannabinoid function in learning, memory and plasticity,” Handbook of Experimental Pharmacology., no. 168, pp. 445–477, 2005. View at Google Scholar · View at Scopus
  15. J. Tasker, “Endogenous cannabinoids take the edge off neuroendocrine responses to stress,” Endocrinology, vol. 145, no. 12, pp. 5429–5430, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. Fernandez-Ruiz, F. Berrendero, M. L. Hernandez, J. Romero, and J. A. Ramos, “Role of endocannabinoids in brain development,” Life Sciences, vol. 65, no. 6-7, pp. 725–736, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Harkany, E. Keimpema, K. Barabas, and J. Mulder, “Endocannabinoid functions controlling neuronal specification during brain development,” Molecular and Cellular Endocrinology, vol. 286, no. 1-2, supplement 1, pp. S84–S90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Parolaro, N. Realini, D. Vigano, C. Guidali, and T. Rubino, “The endocannabinoid system and psychiatric disorders,” Experimental Neurology, vol. 224, no. 1, pp. 3–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Dean, S. Sundram, R. Bradbury, E. Scarr, and D. D. Copolov, “Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use,” Neuroscience, vol. 103, no. 1, pp. 9–15, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Zavitsanou, T. Garrick, and X. F. Huang, “Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 28, no. 2, pp. 355–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. V. S. Dalton, L. E. Long, C. S. Weickert, and K. Zavitsanou, “Paranoid schizophrenia is characterized by increased CB 1 receptor binding in the dorsolateral prefrontal cortex,” Neuropsychopharmacology, vol. 36, no. 8, pp. 1620–1630, 2011. View at Publisher · View at Google Scholar
  22. D. T. Malone, M. N. Hill, and T. Rubino, “Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models,” British Journal of Pharmacology, vol. 160, no. 3, pp. 511–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi, and T. E. Moffitt, “Cannabis use in adolescence and risk for adult psychosis: iongitudinal prospective study,” British Medical Journal, vol. 325, no. 7374, pp. 1212–1213, 2002. View at Google Scholar · View at Scopus
  24. S. Zammit, P. Allebeck, S. Andreasson, I. Lundberg, and G. Lewis, “Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study,” British Medical Journal, vol. 325, no. 7374, pp. 1199–1201, 2002. View at Google Scholar · View at Scopus
  25. N. C. Stefanis, P. Delespaul, C. Henquet, C. Bakoula, C. N. Stefanis, and J. Van Os, “Early adolescent cannabis exposure and positive and negative dimensions of psychosis,” Addiction, vol. 99, no. 10, pp. 1333–1341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. L. P. Spear, “The adolescent brain and age-related behavioral manifestations,” Neuroscience and Biobehavioral Reviews, vol. 24, no. 4, pp. 417–463, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. S. L. Andersen, “Trajectories of brain development: point of vulnerability or window of opportunity?” Neuroscience and Biobehavioral Reviews, vol. 27, no. 1-2, pp. 3–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Berrendero, N. Sepe, J. A. Ramos, V. Di Marzo, and J. J. Fernandez-Ruiz, “Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period,” Synapse, vol. 33, no. 3, pp. 181–191, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Fernandez-Ruiz, F. Berrendero, M. L. Hernandez, and J. A. Ramos, “The endogenous cannabinoid system and brain development,” Trends in Neurosciences, vol. 23, no. 1, pp. 14–20, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Perez-Rosado, J. Manzanares, J. Fernandez-Ruiz, and J. A. Ramos, “Prenatal Δ9-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences,” Brain Research Developmental Brain Research, vol. 120, no. 1, pp. 77–81, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. K. K. Ade and D. M. Lovinger, “Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum,” Journal of Neuroscience, vol. 27, no. 9, pp. 2403–2409, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. R. C. Belue, A. C. Howlett, T. M. Westlake, and D. E. Hutchings, “The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats,” Neurotoxicology and Teratology, vol. 17, no. 1, pp. 25–30, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Rodriguez de Fonseca, J. A. Ramos, A. Bonnin, and J. J. Fernandez-Ruiz, “Presence of cannabinoid binding sites in the brain from early postnatal ages,” NeuroReport, vol. 4, no. 2, pp. 135–138, 1993. View at Google Scholar · View at Scopus
  34. H. D. Burns, K. Van Laere, S. Sanabria-Bohorquez et al., “[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 23, pp. 9800–9805, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Goffin, G. Bormans, C. Casteels et al., “An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam,” Neuropharmacology, vol. 54, no. 7, pp. 1103–1106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Casteels, G. Bormans, and K. Van Laere, “The effect of anaesthesia on [18F]MK-9470 binding to the type 1 cannabinoid receptor in the rat brain,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 6, pp. 1164–1173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Casteels, B. Vanbilloen, D. Vercammen et al., “Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding,” Synapse, vol. 64, no. 8, pp. 617–623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Casteels, E. Lauwers, A. Baitar, G. Bormans, V. Baekelandt, and K. Van Laere, “In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease,” Brain Research, vol. 1316, pp. 153–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Gerard, J. Ceccarini, G. Bormans et al., “Influence of chronic nicotine administration on cerebral type 1 cannabinoid receptor binding: an in vivo micro-pet study in the rat using [18F]MK-9470,” Journal of Molecular Neuroscience, vol. 42, no. 2, pp. 162–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Casteels, C. Vandeputte, J. R. Rangarajan et al., “Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease,” Experimental Neurology, vol. 229, no. 2, pp. 440–449, 2011. View at Publisher · View at Google Scholar
  41. C. Casteels, E. Martinez, G. Bormans et al., “Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 12, pp. 2354–2363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Van Laere, M. Koole, S. M. S. Bohorquez et al., “Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand18F-MK-9470 in healthy subjects,” Journal of Nuclear Medicine, vol. 49, no. 3, pp. 439–445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Sanabria-Bohorquez, T. G. Hamill, K. Goffin et al., “Kinetic analysis of the cannabinoid-1 receptor PET tracer [ 18F]MK-9470 in human brain,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 5, pp. 920–933, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Van Laere, K. Goffin, G. Bormans et al., “Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament,” Archives of General Psychiatry, vol. 66, no. 2, pp. 196–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Gerard, G. Pieters, K. Goffin, G. Bormans, and K. Van Laere, “Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa,” Biological Psychiatry, vol. 70, no. 8, pp. 777–784, 2011. View at Publisher · View at Google Scholar
  46. V. S. Dalton and K. Zavitsanou, “Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain,” Journal of Chemical Neuroanatomy, vol. 40, no. 4, pp. 272–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Zavitsanou, H. Wang, V. S. Dalton, and V. Nguyen, “Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats,” Neuroscience, vol. 169, no. 1, pp. 315–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Verdurand, V. S. Dalton, and K. Zavitsanou, “GABAA receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats,” Brain Research, vol. 1351, pp. 238–245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. Q. Bao, D. Newport, M. Chen, D. B. Stout, and A. F. Chatziioannou, “Perfrmance evalution of the inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards,” Journal of Nuclear Medicine, vol. 50, no. 3, pp. 401–408, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Qi, R. M. Leahy, S. R. Cherry, A. Chatziioannou, and T. H. Farquhar, “High-resolution 3D bayesian image reconstruction using the microPET small-animal scanner,” Physics in Medicine and Biology, vol. 43, no. 4, pp. 1001–1013, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. V. S. Dalton, H. Wang, and K. Zavitsanou, “HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat,” Neurochemical Research, vol. 34, no. 7, pp. 1343–1353, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, vol. 6, Academic Press, 2007.
  53. J. Romero, E. Garcia-Palomero, F. Berrendero et al., “Atypical location of cannabinoid receptors in white matter areas during rat brain development,” Synapse, vol. 26, no. 3, pp. 317–323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. R. G. Pertwee, “Pharmacology of cannabinoid receptor ligands,” Current Medicinal Chemistry, vol. 6, no. 8, pp. 635–664, 1999. View at Google Scholar · View at Scopus
  55. J. L. Wiley, R. L. Barrett, J. Lowe, R. L. Balster, and B. R. Martin, “Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats,” Neuropharmacology, vol. 34, no. 6, pp. 669–676, 1995. View at Publisher · View at Google Scholar · View at Scopus
  56. B. K. Atwood and K. MacKie, “CB2: a cannabinoid receptor with an identity crisis,” British Journal of Pharmacology, vol. 160, no. 3, pp. 467–479, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. V. Di Marzo, M. Bifulco, and L. De Petrocellis, “The endocannabinoid system and its therapeutic exploitation,” Nature Reviews Drug Discovery, vol. 3, no. 9, pp. 771–784, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. S. S. Negus, “Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists,” Biochemical Pharmacology, vol. 71, no. 12, pp. 1663–1670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. R. B. Innis, V. J. Cunningham, J. Delforge et al., “Consensus nomenclature for in vivo imaging of reversibly binding radioligands,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 9, pp. 1533–1539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Ellgren, A. Artmann, O. Tkalych et al., “Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects,” European Neuropsychopharmacology, vol. 18, no. 11, pp. 826–834, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Mato, E. Del Olmo, and A. Pazos, “Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain,” European Journal of Neuroscience, vol. 17, no. 9, pp. 1747–1754, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Van Laere, K. Goffin, C. Casteels et al., “Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18F]MK-9470 PET,” NeuroImage, vol. 39, no. 4, pp. 1533–1541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. D. F. Wong, H. Kuwabara, A. G. Horti et al., “Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR,” NeuroImage, vol. 52, no. 4, pp. 1505–1513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. J. P. Changeux and A. Danchin, “Selective stabilisation of developing synapses as a mechanism for the specification of neuronal networks,” Nature, vol. 264, no. 5588, pp. 705–712, 1976. View at Google Scholar · View at Scopus
  65. D. Purves and J. W. Lichtman, “Elimination of synapses in the developing nervous system,” Science, vol. 210, no. 4466, pp. 153–157, 1980. View at Google Scholar · View at Scopus
  66. M. H. Teicher, S. L. Andersen, and J. C. Hostetter, “Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens,” Developmental Brain Research, vol. 89, no. 2, pp. 167–172, 1995. View at Publisher · View at Google Scholar · View at Scopus